{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"description":"DLT is defined as an event that is clinically significant and not clearly related to disease progression or intercurrent illness that occurred within the DLT observation period of the Cycle 1 timeframe.","groups":[{"description":"Participants received high dose LY3499446 as oral monotherapy BID in 21-day cycles.","id":"OG000","title":"LY3499446 Phase 1 Cohort A1 (High Dose)"},{"description":"Participant received mid dose LY3499446 as oral monotherapy once QOD in 21-day cycles.","id":"OG001","title":"LY3499446 Phase 1 Cohort AO (Mid Dose)"},{"description":"Participants received low dose LY3499446 as oral monotherapy once QD in 21-day cycles.","id":"OG002","title":"LY3499446 Phase 1 Cohort A-2 (Low Dose)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least one dose of study drug and had a dose limiting toxicity.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (21 Day Cycle)","title":"Phase 1: Number or Participants With Dose Limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"Participants"}